Financial Data and Key Metrics Changes - In Q4 2025, Bruker reported revenues of $977.2 million, approximately flat year-over-year, with a currency tailwind of 4.1% and an organic decline of 5.1% [12][26] - For the full year 2025, reported revenues increased by 2.1% to $3.44 billion, with an organic revenue decline of 3.7% [13][32] - Non-GAAP diluted EPS for Q4 2025 was $0.59, down from $0.76 in Q4 2024, reflecting a 22.4% decrease [29] - Non-GAAP operating margin for Q4 2025 was 15.7%, down 240 basis points year-over-year [28] Business Line Data and Key Metrics Changes - The BioSpin group revenue for 2025 was $879 million, declining in the mid-single digits, with solid growth in Chemspeed lab automation offset by declines in NMR instrumentation [15][16] - The CALID group had revenue of $1.2 billion, with constant exchange rate growth in the high single digits, driven by microbiology and infection diagnostics [17] - Bruker Nano revenues for 2025 were $1.1 billion, declining in the low single digits, with solid growth in spatial biology offset by declines in academia/government and industrial markets [18] Market Data and Key Metrics Changes - In Q4 2025, Americas revenue declined in the low teens%, while European revenue declined in the high single digits%, and Asia Pacific revenue grew in the high single digits% [27] - The U.S. biopharma and industrial growth looked stronger in orders in the second half of the year, while U.S. academic/government remained weak [22] Company Strategy and Development Direction - Bruker is focused on expanding its leadership in post-genomic disease research and drug discovery tools, particularly in proteomics and multi-omics [19] - The company aims for significant margin expansion, targeting a 250-300 basis points improvement in operating profit margin for 2026 [11][35] - Bruker plans to leverage its recent acquisitions and product innovations to drive revenue growth in fiscal year 2026 and beyond [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the recovery in demand, particularly in biopharma and industrial research, while acknowledging lingering uncertainties in the U.S. government market [9][49] - The company expects to return to organic revenue growth in the second quarter of 2026, driven by improved order momentum and easier year-over-year comparisons [37][60] Other Important Information - Bruker generated strong free cash flow of over $200 million in Q4 2025, with a focus on cost-saving initiatives exceeding the previously stated range of $100 million-$120 million [7][31] - The company ended fiscal year 2025 with a leverage ratio of approximately 3.1 and plans to continue de-levering actions [32] Q&A Session Summary Question: Margin initiatives and expectations for 2026 - Management discussed the focus on cost initiatives to improve margins, expecting annualized savings to exceed $140 million [42] Question: Academic and government customer interactions - Management noted that while U.S. academic/government orders were weak, there is cautious optimism for improvement in the second half of the year [49] Question: Revenue pacing through the year - Management indicated that both easier comparisons and improving order momentum would contribute to revenue growth starting in Q2 2026 [60] Question: Expectations for end markets - Management expects low single-digit organic growth in biopharma and semi, with microbiology showing stronger performance [65]